Psychedelics are returning to medicine. A psilocybin formulation will likely receive US approval soon–a historic success for the movement's long struggle against prohibition. Yet medicalization and commodification transform psychedelics. These formulations are patented; next-level psychedelics are developed by investors of the Peter Thiel kind and supported by Trump—optimized for short effects to fit clinical practice, some seeking to eliminate the hallucinogenic effects. Will hedonism be lost?
